Full-Time

Sr. Manager

Medical Science Liaison, Central

Posted on 9/10/2024

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology

Compensation Overview

$200k - $235kAnnually

+ Performance Bonus + Equity

Senior

Remote in USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Communications
Requirements
  • Candidates with a PharmD, Ph.D., MD, Genetic Counseling, as well as other advanced healthcare degrees or relevant experience, will be considered
  • 3+ years of medical affairs or field medical experience with a verifiable record of high performance
  • Excellent interpersonal communication and presentation skills (including networking)
  • Able to participate in a scientific dialogue with KOL’s and researchers
  • Excellent teaching skills and ability to present and discuss scientific material clearly and concisely
  • Proven ability to create and sustain relationships with industry leaders
  • Skilled in clinical research and an understanding of the process of pharmaceutical product development and approval
  • Demonstrated ability to organize, prioritize, and work effectively with minimal supervision in a constantly changing environment
  • Travel 50-60% of the time depending on territory size; evening and weekend work will be involved with some variation based upon the demands of the business imperatives
Responsibilities
  • Developing relationships with various healthcare professionals and providing them with credible, fair, balanced, scientific information
  • Be a major source of balanced medical information for HCPs and will be skilled in issues management and addressing unsolicited questions about safety and off-label use of products based on available scientific data
  • Territory planning, identifying new external stakeholders, and understanding therapeutic area educational and data gaps in the community will be key activities. This plan may be dynamic with respect to the molecule, molecule life-cycle, therapeutic area, and territory. The Senior MSL will liaise with key internal stakeholders to build a comprehensive action-oriented plan
  • Expected to become a therapeutic area and product expert. This will be evidenced by regular review of relevant literature and participation in scientific congresses and conferences, including training sessions, to establish and maintain an up-to-date knowledge base
  • Be instrumental in internal training and communication. Knowledge sharing, including KOL and site profiling, and education both internally and externally will be a key area of responsibility
  • Assist in the identification of potential investigators and research projects. This may include assistance with investigator-sponsored trial process, sponsored study site identification, recruitment strategies, and collaboration with clinical operations

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on therapies for specific diseases while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create significant therapeutic improvements by targeting diseases at their genetic source. With over 15 drug programs aimed at 20 different genetic diseases, BridgeBio aims to reduce the time it takes to bring treatments to market. The company promotes a culture of independent thinking and transparency, which supports quick, data-driven decision-making.

Company Stage

IPO

Total Funding

$704.4M

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

20%

1 year growth

52%

2 year growth

101%
Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with PANTHERx Rare ensures strategic patient access to therapies.
  • Recent investments indicate strong financial backing and confidence in BridgeBio.
  • Launch of BridgeBio Oncology Therapeutics expands into precision oncology with $200m funding.

What critics are saying

  • Alnylam's Amvuttra poses competitive pressure on BridgeBio's Attruby.
  • KRAS inhibitors face significant scientific and clinical hurdles.
  • Decentralized model may challenge cohesive strategic direction and resource allocation.

What makes BridgeBio unique

  • BridgeBio employs a decentralized subsidiary model for rapid drug development.
  • Focus on genetic diseases with well-understood causes allows targeted therapeutic interventions.
  • Innovative use of genome sequencing and molecular biology for personalized medicine.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE